• Overview
  • Eligibility
  • More info
  • Locations

Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Short Children Born Small for Gestational Age. (NCT02770157)

A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin® in short children born small for gestational age.
  • Drug: DA-3002
    • Drug: Genotropin®
      Ages eligible for Study
      4 Years to 16 Years
      Genders eligible for Study
      All
      Accepts Healthy Volunteers
      No
      Inclusion Criteria:
      • Chronological Age ≥ 4
      • Before the adolescence, Tuner stage I (breast)
      • Height <3rd percentile for age
      • Normal thyroid function
      Exclusion Criteria:
      • Growth hormone was administered for 12 months or longer in the past
      • Treated with estrogen or adrenal androgens for 12 months or longer in the past
      • Malignancy, CNS Trauma, Psychiatric Disorder
      • endocrine and/or metabolic disorders
      • growth failure caused by other disorders

      1 locations

      Korea, Republic of (1)
      • Samsung Medical Center
        recruiting
        Seoul, Korea, Republic of
      Status:
      recruiting
      Type:
      Interventional
      Phase:
      Start:
      31 January, 2016
      Updated:
      17 September, 2017
      Participants:
      75
      Apply
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!